Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
作者信息
Breccia Massimo, Federico Vincenzo, Loglisci Giuseppina, Salaroli Adriano, Serrao Alessandra, Alimena Giuliana
出版信息
Haematologica. 2011 Oct;96(10):e41-2. doi: 10.3324/haematol.2011.048991.
Abstract
摘要
相似文献
1
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
Haematologica. 2011 Oct;96(10):e41-2. doi: 10.3324/haematol.2011.048991.
2
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Haematologica. 2011 Mar;96(3):349-52. doi: 10.3324/haematol.2010.030023.
3
Progenitor cells and classification of myelodysplastic and myeloproliferative disorders.
Lancet. 1985 Nov 30;2(8466):1240. doi: 10.1016/s0140-6736(85)90764-0.
4
Progenitor cells and classification of myelodysplastic and myeloproliferative disorders.
Lancet. 1985 Oct 19;2(8460):885. doi: 10.1016/s0140-6736(85)90145-x.
5
Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?
Leuk Lymphoma. 2008 Jul;49(7):1225-7. doi: 10.1080/10428190802187189.
6
Studies on blood and bone marrow findings of myelodysplastic syndromes: evaluation of proposals for classification of myelodysplastic syndromes.
Proc Chin Acad Med Sci Peking Union Med Coll. 1988;3(1):7-11.
7
Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.
MedGenMed. 2005 Mar 14;7(1):21.
8
The WHO classification of the myelodysplastic syndromes.
Exp Oncol. 2004 Sep;26(3):166-9.
9
The myelodysplastic syndromes and myeloproliferative disorders.
Clin Lab Sci. 2004 Fall;17(4):223-34.
10
The JAK2 V617F mutation is rare in RARS but common in RARS-T.
Leukemia. 2006 Nov;20(11):2060-1. doi: 10.1038/sj.leu.2404373. Epub 2006 Aug 24.
引用本文的文献
1
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):418-425. doi: 10.1182/hematology.2020000126.
2
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.
3
The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.
Haematologica. 2014 Mar;99(3):e31-2. doi: 10.3324/haematol.2013.101055. Epub 2014 Jan 24.
4
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.
Curr Hematol Malig Rep. 2013 Dec;8(4):351-60. doi: 10.1007/s11899-013-0172-3.
5
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.
Haematologica. 2012 Feb;97(2):e2. doi: 10.3324/haematol.2011.059808.
本文引用的文献
1
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Haematologica. 2011 Mar;96(3):349-52. doi: 10.3324/haematol.2010.030023.
2
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.
3
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Leuk Res. 2011 Feb;35(2):159-62. doi: 10.1016/j.leukres.2010.06.005. Epub 2010 Jul 1.
4
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
J Clin Oncol. 2007 Aug 10;25(23):3503-10. doi: 10.1200/JCO.2006.08.5696.
Zotero 插件